Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today

In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous system, were trading 13.9% higher as of 1:35 p.m. EDT on Wednesday.

Here's a review of the key financial numbers from the second quarter:

Acadia also shared a few non-financial highlights from the quarter with investors:

Source: Fool.com